Exosome Diagnostics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2008-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.exosomedx.com
Clinical Trials
9
Active:0
Completed:3
Trial Phases
1 Phases
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (100.0%)ExoDx Prostate Evaluation in Active Surveillance Patient Population
Recruiting
- Conditions
- Prostate Cancer
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 750
- Registration Number
- NCT05572099
- Locations
- 🇺🇸
Chesapeake Urology, Towson, Maryland, United States
Urine Biomarker for Kidney Transplant Rejection
Not yet recruiting
- Conditions
- Graft Rejection
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 750
- Registration Number
- NCT05072951
Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy
Completed
- Conditions
- Urologic Cancer
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04720599
- Locations
- 🇺🇸
Chesapeake Urology Research Associates, Baltimore, Maryland, United States
🇺🇸New Jersey Urology, Voorhees, New Jersey, United States
🇩🇪Klinikum der Universität München, München, Germany
ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting
Terminated
- Conditions
- Prostate Cancer
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT04357717
- Locations
- 🇺🇸
Chesapeake Urology Research Associates, Baltimore, Maryland, United States
🇺🇸New Jersey Urology, Voorhees, New Jersey, United States
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03236675
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Ochsner Medical Center, New Orleans, Louisiana, United States
- Prev
- 1
- 2
- Next
News
No news found